FierceBiotechOriginal article
{"a":[{"_":"ESC26: AstraZeneca's heart failure drug shows promise in ph. 2 trial","$":{"href":"/biotech/esc26-astrazenecas-heart-failure-drug-shows-promise-ph-2-trial","hreflang":"en"}}]}
Phase 2positiveOral relaxin agonistPositive
AI Analysis
Summary
AstraZeneca's oral relaxin agonist demonstrated encouraging Phase 2b results in chronic heart failure, showing improvements in cardiac function measures across two patient populations. The positive data supports continued development of the candidate therapy.
Clinical Trial Data
Phase
2b
Primary Endpoint
Met
Outcome Details
Improved measures of cardiac function across two patient groups
Importance:7/10
Sentiment:
0.75
Phase 2bHeart failureOral drugCardiac functionESC26 Conference
Related Companies
Read the original article
Published by FierceBiotech on August 31, 2026 10:47 AM